Firefly Neuroscience (AIFF) shares were up more than 170% in recent trading after the company said it was accepted into the Nvidia (NVDA) Connect program.
Intraday trading volume catapulted to over 155 million shares from a daily average of about 2.48 million.
Lipella Pharmaceuticals (LIPO) said its treatment candidate for oral lichen planus showed "clinically meaningful" reductions in pain, ulceration, and inflammation across all key metrics in a phase 2a trial.
Shares soared about 36% as intraday trading volume surged to over 37.2 million from a daily average of about 1.59 million.
Travere Therapeutics (TVTX) said it completed a meeting with the US Food and Drug Administration and plans to submit a supplemental new drug application for approval of Filspari for focal segmental glomerulosclerosis, a rare kidney disorder.
Wedbush raised its price target on the stock to $30 from $26 while maintaining its outperform rating.
Shares of Travere rose 13% as intraday trading volume climbed to over 3.62 million from a daily average of about 1.29 million.
Price: 8.01, Change: +4.91, Percent Change: +158.39
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。